Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.35 |
| ▸ | NAT1 | P18440 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796826 | 1.00 | MEN1 (0.40) | MEN1KMT2AHPGDPOLBMAPT | |
| SCHEMBL8533657 | 0.88 | GAA (0.39) | MEN1KMT2AHPGDPOLBMAPT | |
| SCHEMBL8533654 | 0.88 | GAA (0.39) | MEN1KMT2AHPGDPOLBMAPT | |
| SCHEMBL7803519 | 0.79 | MEN1 (0.43) | MEN1KMT2APOLBMAPTGAA | |
| SCHEMBL7803520 | 0.79 | MEN1 (0.43) | MEN1KMT2APOLBMAPTGAA | |
| SCHEMBL7805141 | 0.76 | PTGS2 (0.53) | MEN1KMT2AGAAALDH1A1PTGS2 | |
| SCHEMBL7805137 | 0.76 | PTGS2 (0.53) | MEN1KMT2AGAAALDH1A1PTGS2 | |
| SCHEMBL7805135 | 0.76 | PTGS2 (0.53) | MEN1KMT2AGAAALDH1A1PTGS2 | |
| SCHEMBL8580786 | 0.76 | KDM4E (0.35) | MEN1KMT2AHPGDPOLBMAPT | |
| SCHEMBL8991952 | 0.76 | KDM4E (0.35) | MEN1KMT2AHPGDPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | PANETTA JILL (US) | 2001-08-30 | — | — | US | disclosed |
| US-5981523-A | ADMINISTERING THIOMORPHOLINONE COMPOUND TO THE PATIENT SUFFERING FROM MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0779282-A1 | Thiomorpholinone compounds for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018437-A1 | NOVEL COMPOUNDS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | TXNRD3, TXNRD2, CTH | MEN1 3945/4885KMT2A 1634/4885HPGD 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.